Factors Associated with Nonalcoholic Fatty Liver Disease in a Non-Overweight/Obese and Overweight/Obese Chinese Population at Risk for Metabolic Syndrome: A Cross-Sectional Multicenter Study
- 23 September 2024
- journal article
- research article
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 23 (1) , 41-52
Abstract
Background: To investigate the association of demographic, clinical, and metabolic factors with nonalcoholic fatty liver disease (NAFLD) in a non-overweight/obese and overweight/obese Chinese population at risk for metabolic syndrome. Patients and Method: A cross-sectional multicenter study was conducted using convenience sampling from eight selected counties/cities in Zhejiang, China, between May 2021 and September 2022. Demographics, epidemiological, anthropometric, and clinical characteristics were obtained from a questionnaire. Least absolute shrinkage and selection operator (LASSO)-logistic regression analysis was used to identify the variables associated with NAFLD. Receiver operating characteristic (ROC) curve analysis and decision curve analysis (DCA) were performed to evaluate the diagnostic value and clinical utility of the variables and models. Results: A total of 1739 patients were enrolled in the final analysis, 345 (19.8%) were non-overweight/obese and 1394 (80.2%) were overweight/obese participants. There were 114 (33.0%) and 1094 (78.5%) patients who met the criteria for NAFLD in the non-overweight/obese participants and the overweight/obese participants respectively. Older age, current smoking, higher triglyceride (TG) levels, higher AST levels, higher albumin levels, lower insulin levels, and higher controlled attenuation parameter (CAP) scores were associated with NAFLD in both non-overweight/obese and overweight/obese participants. The combination of TG+CAP scores had strong predictive values for NAFLD, especially in non-overweight/obese (Area Under Curve = 0.812, 95% confidence interval: 0.764-0.863). DCA showed a superior net benefit of the TG+CAP score over other variables or models, suggesting a better clinical utility in identifying NAFLD. Conclusions: More stringent lipid management strategies remain essential, and the convenience and efficacy of transient elastography for liver steatosis should be recognized, especially in the non-overweight/obese population.Keywords
This publication has 35 references indexed in Scilit:
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Journal of Hepatology, 2024
- 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identicalJournal of Hepatology, 2023
- Can we use old NAFLD data under the new MASLD definition?Journal of Hepatology, 2023
- Changing epidemiology, global trends and implications for outcomes of NAFLDJournal of Hepatology, 2023
- Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry studyMetabolism, 2022
- Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective studyThe Lancet Oncology, 2021
- The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysisHepatology International, 2020
- New trends on obesity and NAFLD in AsiaJournal of Hepatology, 2017
- Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinationsJournal of Hepatology, 2014
- Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: Role of tumor necrosis factor-αNutrition, Metabolism and Cardiovascular Diseases, 2007